Search for: [Abstract = "Group with endometriosis were divided according to the severity of the disease by rAFS, location and symptoms. The ovarian cancer group was divided according to the clinical stage by FIGO, histological type and stage, presence of ascites. Excluded\: women using contraception, hormone therapy, other gynecological diseases, the presence of inflammation associated with systemic diseases, diabetes, thyroid disease. The concentration of sHLA\-G in serum were measured by ELISA \(ExBio, Czech Republic\). In 98% of women with endometriosis sHLA\-G was detected in serum. It has been shown statistically significant difference between I and IV of the severity of endometriosis by rAFS, concentrations increased with increasing sophistication. sHLA\-G levels were at a similar level, taking into account the symptoms of endometriosis. Not shown a correlation between sHLA\-G in serum and the age of the patients. It was found higher sHLA\-G in women\: with deep endometriosis the endometrial cysts, with deep endometriosis in the secretory phase of the proliferative phase, secretory phase in deep endometriosis compared to cysts. In 94% of patients with ovarian cancer sHLA\-G was present in serum. It was shown the significantly higher levels of sHLA\-G in FIGO stages III and IV than in I and II. There were no significant differences depending on the differentiation and histological type, presence o"]

Number of results: 1